截至2025年12月18日收盘，深圳国际（00152）报收于8.39元，较前一交易日上涨0.48%，该股当日开盘 8.38元，最高8.48元，最低8.37元，成交额达3190.34万元。近52周最高8.74元，最低6.16元。 《自愿性公告:联营公司增资扩股之进展》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 深圳国际控股有限公司于近日发布公告，宣布其联营公司深圳航空已通过公开挂牌方式成功引入新投资 者深圳市鲲航投资合伙企业（有限合伙），并签署增资协议。中国国航及鲲航投资将分别出资约人民币 20.82亿元和人民币20亿元，认购深圳航空新增注册资本，完成第一阶段增资。本次增资后，深圳航空 注册资本增加，本公司持股比例由49%摊薄至约28.09%，中国国航及鲲航投资将分别持有51%及约 20.91%股权，深圳航空仍为公司的联营公司。后续增资将由中国国航及鲲航投资适时签署协议推进， 公司持股比例预计将进一步摊薄。公司将于有重大进展时按上市规则另行公告。 最新公告列表 ...

Group 1 - Shenzhen International (00152.HK) announced that its associate company, Shenzhen Airlines, plans to conduct a phased capital increase totaling 16 billion RMB [1] - The group has decided not to participate in the capital increase, which will introduce Kunhang Investment as a new investor through a public bidding process [1] - The capital increase agreement and related documents are set to be signed on December 18, 2025, with China National Aviation and Kunhang Investment contributing approximately 2.082 billion RMB and 2 billion RMB respectively in the first phase [1] Group 2 - Following the completion of the first phase of the capital increase, the group's stake in Shenzhen Airlines will be diluted from 49% to approximately 28.09% [1] - China National Aviation and Kunhang Investment will hold 51% and approximately 20.91% of Shenzhen Airlines respectively, which will continue to be an associate company of Shenzhen International [1] - Further dilution of the group's stake is expected as China National Aviation and Kunhang Investment will sign relevant agreements for subsequent capital increases in due course [1]

智通财经APP讯，深圳国际(00152)发布公告，有关公司的联营公司深圳航空拟分阶段进行增资扩股，合 共增资人民币160亿元，而集团决定不参与增资。深圳航空已通过公开挂牌方式成功引入深圳市鲲航投 资合伙企业(有限合伙)作为新投资者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航 及鲲航投资将分别出资约人民币20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本。于第一 阶段增资完成后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持 有深圳航空51%及约20.91%的股权，深圳航空将继续为公司的联营公司。中国国航及鲲航投资将就后续 增资适时签署相关协议，集团所持深圳航空的股权预计将进一步被摊薄。 ...

智通财经APP讯，深圳国际(00152)发布公告，有关公司的联营公司深圳航空拟分阶段进行增资扩股，合 共增资人民币160亿元，而集团决定不参与增资。深圳航空已通过公开挂牌方式成功引入深圳市鲲航投 资合伙企业(有限合伙)作为新投资者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航 及鲲航投资将分别出资约人民币20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本。于第一 阶段增资完成后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持 有深圳航空51%及约20.91%的股权，深圳航空将继续为公司的联营公司。中国国航及鲲航投资将就后续 增资适时签署相关协议，集团所持深圳航空的股权预计将进一步被摊薄。 ...

深圳航空已通过公开挂牌方式成功引入深圳市鲲航投资合伙企业(有限合伙)("鲲航投资")作为新投资 者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航及鲲航投资将分别出资约人民币 20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本("第一阶段增资")。于第一阶段增资完成 后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持有深圳航空 51%及约20.91%的股权，深圳航空将继续为公司联营公司。中国国航及鲲航投资将就后续增资适时签署 相关协议，集团所持深圳航空之股权预计将进一步被摊薄。 格隆汇12月18日丨深圳国际(00152.HK)公布，有关公司联营公司深圳航空拟分阶段进行增资扩股，合共 增资人民币160亿元，而集团决定不参与增资。 来源：格隆汇APP ...

深圳航空已通过公开挂牌方式成功引入深圳市鲲航投资合伙企业(有限合伙)("鲲航投资")作为新投资 者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航及鲲航投资将分别出资约人民币 20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本("第一阶段增资")。于第一阶段增资完成 后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持有深圳航空 51%及约20.91%的股权，深圳航空将继续为公司联营公司。中国国航及鲲航投资将就后续增资适时签署 相关协议，集团所持深圳航空之股权预计将进一步被摊薄。 格隆汇12月18日丨深圳国际(00152.HK)公布，有关公司联营公司深圳航空拟分阶段进行增资扩股，合共 增资人民币160亿元，而集团决定不参与增资。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事會命 深圳國際控股有限公司 聯席公司秘書 劉旺新 2025年12月18日 於本公告日期，董事會的成員包括執行董事李海濤先生、劉征宇先生、王沛航先生 及劉秀麗女士；非執行董事蔡曉平先生；以及獨立非執行董事潘朝金先生、曾志博 士、王國文博士及丁春艷教授。 （於百慕達註冊成立之有限公司） （股份代號：00152） 自願性公告 聯營公司增資擴股之進展 茲提述深圳國際控股有限公司（「本公司」，連同其附屬公司統稱為 「本集團」）日期為 2025 年 8 月 28 日的自願性公告（「該公告」）， 內容有關本公司之聯營公司深圳航空擬分階段進行增資擴股，合共增 資人民幣 160 億元，而本集團決定不參與增資。除非文義另有所指，本 公告所用之詞彙與該公告所界定者具有相同涵義。 本公司僅此宣佈，深圳航空已通過公開掛牌方式成功引入深圳市鯤航 投資合夥企業（有限合夥）（「鯤航投資」）作為新投資者，並於 2025 年 12 ...

Core Insights - The Shenzhen International Energy Storage Technology Exhibition 2026 will take place from August 26 to 28, 2026, at the Shenzhen International Convention and Exhibition Center, focusing on the energy storage industry and its advancements [1][9]. Industry Overview - China, as the world's largest energy producer and consumer, has established a comprehensive clean energy equipment manufacturing industry chain, including hydropower, nuclear power, wind power, and solar energy, leading to unprecedented opportunities for the energy storage sector [1]. - According to the National Energy Administration, by the first half of 2024, the cumulative installed capacity of new energy storage projects in China reached 44.44 million kilowatts (99.06 million kilowatt-hours), representing a growth of over 40% compared to the end of 2023 [1]. Exhibition Details - The exhibition will showcase a wide range of energy storage technologies and materials, energy storage power stations, EPC engineering related facilities, liquid cooling technology, grid dispatch and automation control, and intelligent metering and electricity management systems [2]. - Over 800 leading global suppliers from the energy storage industry are expected to participate, with an exhibition area exceeding 40,000 square meters, making it the largest and most professional international energy storage event in South China [2]. Exhibition Scope - The exhibition will include various sections such as energy storage technology, energy storage systems and solutions, battery technology, battery materials and components, and hydrogen energy and fuel cell industries [6][7]. - Specific areas will feature different types of energy storage batteries, systems, and equipment, including lithium-ion batteries, sodium-sulfur batteries, supercapacitors, and various energy management systems [6][7].

Core Insights - The event "2025 Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition" was held in Hong Kong, focusing on "Innovative Drugs and Devices, Collaborative Win-Win" [1] - Over 120 companies, universities, and research institutions participated, with more than 300 representatives attending [1] - The exhibition showcased the "hard power" of the Greater Bay Area's pharmaceutical and medical device industry, featuring advanced medical equipment and innovative pharmaceutical achievements [1] Group 1 - The event adopted a "conference + exhibition" model to explore cutting-edge technology trends and collaborative development initiatives [1] - It aimed to deepen cross-border cooperation between Shenzhen and Hong Kong in the pharmaceutical and medical device sectors, contributing to high-quality development in the Greater Bay Area [1] - Notable exhibits included advanced surgical robots and automated models for traditional Chinese medicine, highlighting the industrial vitality of both regions [1] Group 2 - Top experts from institutions like the Chinese Academy of Sciences and the U.S. National Academy of Inventors delivered keynote speeches on topics such as infrared fluorescence imaging and clinical applications of surgical robots [1] - The organizers expressed intentions to further integrate industrial resources and align with international standards to create a closed-loop ecosystem of "research-industry-capital" [1] - This initiative is expected to help the Greater Bay Area establish itself as a world-class hub for the pharmaceutical and medical device industries [1]

Core Insights - The event "2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition Hong Kong Station" focuses on the theme "Innovative Drugs and Devices, Collaborative Win-Win" and aims to deepen cross-border cooperation in the pharmaceutical and medical device sectors between Shenzhen and Hong Kong [1] Group 1: Event Overview - The event is guided by multiple health and regulatory bodies from Shenzhen and Hong Kong, featuring a "conference + exhibition" model to explore cutting-edge technology trends and collaborative development measures [1] - Over 300 representatives from more than 120 enterprises, universities, and research institutions participated, showcasing significant medical devices and innovative pharmaceutical products [4] Group 2: Expert Contributions - Notable experts shared insights on various topics, including the application prospects of infrared fluorescence imaging in precision medicine and global trends in digital healthcare [2] - The discussions highlighted the importance of industry-academia-research collaboration for innovation [2] Group 3: Collaborative Achievements - A series of landmark collaborative achievements were announced, including the launch of the GCOG precision treatment clinical trial and the establishment of a collaborative platform for international clinical trials in the Greater Bay Area [3] - Several partnerships were formed in key areas such as cell gene therapy and drug development, aiming to create a "research-application" integration platform and an international service network [3] Group 4: Innovation Showcase - The event featured high-performance medical devices such as surgical robots and automated immunoassay analyzers, demonstrating the industrial strength and innovative vitality of the Shenzhen-Hong Kong region [4] Group 5: Future Development - The forum focused on themes like cell and gene therapy and opportunities in innovative drug and device development, providing intellectual support for industry growth [5] - The event serves as a model for soft connectivity in the Greater Bay Area's pharmaceutical and medical device industry, promoting a new model of industrial linkage between Shenzhen and Hong Kong [5]